These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27615008)

  • 1. Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.
    Okada K; Kotani K; Ebihara K; Yamazaki H; Ishibashi S
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1004-1008. PubMed ID: 27615008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
    Hwang YC; Kim JH; Lee BW; Lee WJ
    Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
    Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
    J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
    Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
    J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
    Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
    J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
    Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
    Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
    Wang H; Yao G; Chen X; Ouyang J; Yang J
    Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
    Tabuchi H; Maegawa H; Tobe K; Nakamura I; Uno S
    Endocr J; 2019 Jan; 66(1):31-41. PubMed ID: 30393249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
    Sugimoto K; Abe I; Minezaki M; Takashi Y; Ochi K; Fujii H; Ohishi H; Yamao Y; Kudo T; Ohe K; Abe M; Ohnishi Y; Shinagawa T; Mukoubara S; Kobayashi K
    Drug Discov Ther; 2019; 13(6):322-327. PubMed ID: 31956230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Endocr J; 2021 Aug; 68(8):905-918. PubMed ID: 33827996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
    Miura H; Sakaguchi K; Okada Y; Yamada T; Otowa-Suematsu N; So A; Komada H; Hirota Y; Ohara T; Kuroki Y; Hara K; Matsuda T; Kishi M; Takeda A; Yokota K; Tamori Y; Ogawa W
    J Diabetes Investig; 2019 Sep; 10(5):1254-1261. PubMed ID: 30688412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
    Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
    Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
    Kutoh E; Wada A; Murayama T; Hirate M
    Drug Res (Stuttg); 2016 Jul; 66(7):345-50. PubMed ID: 27056638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
    Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
    Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
    Kaku K; Isaka H; Sakatani T; Toyoshima J
    J Diabetes Investig; 2020 May; 11(3):662-671. PubMed ID: 31743569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
    Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
    Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.